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Abstract 
Background 
Iron is an important metal, essential for the health and function of mammalian cells. Despite 
its key role, iron deficiency in humans is common worldwide, often leading to significant 
health issues within the population. In this study we aimed to evaluate the potential for using 
iron-enriched baker’s yeast as a source of iron, especially for the protection and recovery 
from conditions related to anemia. 
Methods 
Iron-enriched yeast was prepared by cultivating cells on basal medium comprising different 
concentrations of iron. The effects of iron supplementation on animal health were assessed by 
feeding anemic rats with a variety of diets containing either inorganic iron, or iron-enriched 
yeast. Body weight, iron bioavailability, blood parameters, and the activity of iron containing 
enzymes (catalase) were studied.  
Results 
Iron accumulation in yeast cells increased with iron concentration, reaching a maximum of 15 
mg/g when 32 mM Fe was applied. Rat groups fed on iron enriched yeast gave the highest 
feed efficiency, iron bioavailability and hemoglobin concentration. The source of iron 
supplementation influenced catalase activity in kidney tissues, increasing from 70 U/g tissue 
in anemic rats to 90 U/g tissue (inorganic iron salt), 110 U/g tissue (inorganic iron salt and 
non-enriched dry yeast), 145 U/g tissue (iron-enriched yeast 15 mg Fe/g) and 115 U/g tissue 
(iron-enriched yeast 30 mg Fe/g). The histological study of tissues from liver, kidney, heart, 
and spleen of rats from different groups showed that the damage observed in tissues of 
anemic rats, was not observed after feeding with iron-enriched yeasts. 
Conclusion 
The results demonstrate that ingestion of iron-enriched yeast is more efficient than inorganic 
treatment in recovery from iron deficiency, including tissue recovery in rats. 
Key Words: Saccharomyces cerevisiae, Anemia, Fe, metal ions, malnutrition 
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Introduction 
Although iron is an abundant metal, it has low bioavailability, and iron deficiency represents 
one of the most common nutritional deficiencies worldwide with significant implications to 
public health [1]. The average adult male (70 kg) has a total body iron content of 
approximately 4 grams, which remains relatively constant throughout adult life  [2]. This is 
maintained by balancing loss of iron with assimilation via nutritional intake. Persistent 
deviation in iron intake can result in either iron deficiency, or iron overload (hemosiderosis 
and hemochromatosis) [2]. The most obvious manifestation of iron deficiency is anemia, but 
lack of iron can also have an adverse effect on the immune system [3, 4] and cognitive 
development [5, 6]. Iron is an essential nutrient since iron cofactors, including heme and 
iron-sulfur clusters, are required for the activity of a number of enzymes involved in a range 
of cellular processes. Furthermore, iron is also an important component of molecules that 
undergo redox reactions in cells [7, 8]. Anemia and iron deficiency may cause serious 
diseases, for example, anemia and iron deficiency are quite prevalent in patients with heart 
failure. In the past few years, there has been an enormous interest in the subject of iron 
deficiency and its management in patients with heart failure [9].  
Since leavened bread, produced using Saccharomyces cerevisiae (baker’s yeast), is a staple 
component of diets in many areas of the world, the potential for using yeast biomass 
enriched with iron as a feed supplement has the potential to deliver a safe and efficient 
mechanism for the prevention or recovery from anemia. Previous studies have shown that 
iron bound to organic carriers, such as cytochrome C, catalase and other proteins and 
enzymes in yeast cells, are more easily absorbed and have a reduced potential to be toxic 
[10]. In addition, yeast biomass is known to be a good source of protein, amino acids and 
vitamins, and has been shown to have a positive nutritional impact in animals and humans 
[10]. Despite the suitability of yeast for nutrient transfer, the uptake, storage and utilization 
of iron in Saccharomyces cerevisiae cells is tightly regulated. In particular, the metal uptake 
and assimilation processes are complex and dependent on the chemistry of metal ions, 
specific surface properties of the organism, cell physiology and the physico- chemical 
influence of the environment [10]. Consequently, in this study the capacity of a baker’s yeast 
strain to assimilate iron was determined, and the resulting iron-enriched baker’s yeast was 
evaluated for its potential in alleviating symptoms of iron deficiency in Wistar rats.  
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Materials and Methods 
Preparation of iron-enriched yeast 
A commercial baker's yeast strain was obtained and isolated from the local market (Aleppo, 
Syria). Yeast propagation was conducted in 250 ml Erlenmeyer flask containing 100 ml basal 
medium (20g/l glucose, 0.5g/l yeast extract, 5g/l ammonium sulphate, 1g/l potassium 
dihydrogen phosphate, 0.5g/l magnesium sulphate, pH adjusted to 5.2 with 5N NaOH). Yeast 
cultures were enriched with iron by supplementation with ammonium iron (III) citrate in 
concentrations of 0.5, 1, 2 and 4 % (W/V) corresponding to 16, 32, 64 and 128 mM Fe. The 
cultures were incubated at 30°C for 24 h, with shaking at 150 rpm. In each instance the entire 
cell culture was recovered by centrifugation, excess liquid was decanted and samples were 
desiccated using a drying oven (Memmert, Egypt). Dried yeast samples were collected and 
used for further analysis (iron content and as a nutritional supplement) as described below. 
Evaluation of iron content in iron enriched yeast 
After 24 h cultivation cultures were centrifuged (5 min, 4000 g) and the supernatant 
discarded. The pellet was washed three times with distilled water in order to remove loosely 
associated fraction of iron from yeast cell surface. Washed yeast biomass was dried at 105°C 
until a constant mass was achieved, and digested by adding 1 ml of 65 % (v/v) HNO3 to 20 
mg dry biomass, followed by heating for 30 min at 140°C. After cooling, samples were 
diluted with distilled water to a final volume of 5 ml and the content of iron was analyzed by 
Flame Atomic Absorption Spectrometry (FAAS) in the Agricultural Research Center, Giza, 
Egypt. The amount of total iron was calculated per gram of dry weight (mg Fe/g-1 dry wt.) as 
described previously [10]. 
Animals and diets 
Forty-eight newly weaned male and female Wistar rats (initial body weight, 75 - 85g) were 
obtained and housed individually in stainless steel, wire mesh bottom cages. A 12-h light: 
dark cycle and an environmental temperature of 25 ±2°C were maintained. Newly weaned 
rats were chosen since individuals of this age can be considered to be similar irrespective of 
gender; physiological, hormonal or metabolic changes are not observed between males and 
females at this early stage of life. This was verified in-house by analysis of data, which 
showed that there was no difference between young rats based on gender distinction (data not 
shown).  Rats were randomly assigned to one of six dietary groups (eight rats per group) as 
illustrated in Fig.1. The control group was fed on basal diet containing 30mg of Fe per 
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kilogram of diet for 56 days (total experiment time).  Precise composition of the basal diet 
used was based on Sun et al [11] and shown below. 
Iron deficiency was induced as described by Hamdaoui et al [12] with minor modifications: a 
low iron basal diet (3mg/Kg) was provided in conjunction with bleeding of 1-2 ml of blood 
every week for four weeks until the Fe and Hemoglobin reached a designated low level (109-
112 g/L Hemoglobin and 3 mg body iron) . These anemic rats were assigned to five groups of 
8 rats (four males and four females). Groups were examined by feeding on one of the 
following diets for an additional 28 days: Group 1 was fed on basal Fe-deficient diet (no iron 
added). Group 2 was fed on basal Fe-deficient diet plus FeSO4.7.H2O (30mg Fe/kg diet) 
Group 3 was fed on basal Fe-deficient diet plus FeSO4.7.H2O (30 mg Fe/kg diet) plus 1 g of 
non-enriched yeast per kg diet. Group 4 was fed on basal Fe-deficient diet plus iron-enriched 
yeast (containing 15 mg Fe/kg diet). Group 5 was fed on basal Fe-deficient diet plus iron-
enriched yeast (containing 30 mg Fe/kg diet). Total food intake was determined at the end of 
the experiment; it should be noted that in each instance all animals were marginally under-fed 
in order to ensure that each individual ingested the total quantity of food provided. 
The body weight of rats was measured every week throughout the 56 days of dietary 
treatment. Blood (0.5ml) was collected after 14, 21, 28, 42, and 56 days of the dietary 
program from their eyes into heparinized micro capillary tubes. 
Basal Diet was prepared as follows: Skimmed milk(50% casein), 400 g/Kg diet; Corn starch, 
603 g/Kg; Vegetable oil, 80 g/Kg; Sucrose, 50 g/Kg; Mineral mix, 40 g/Kg; Vitamin mix, 10 
g/Kg.  
The mixtures of minerals and vitamins were prepared according to [11] as follows: 
Vitamin mix contained the following (g/kg mix): inositol, 25.0; ascorbic acid, 5.0; calcium 
pantothenate, 0.67; thiamine hydrochloride, 0.27; pyridoxine hydrochloride, 0.53; nicotinic 
acid, 1.0; menadione, 0.25; riboflavin, 0.27; p- amino benzoic acid, 0.50; folic acid, 0.067; 
biotin, 0.26; all-rac-a-tocopherol acetate, 3.60; retinyl palmitate, 0.034; cholecalciferol, 0.21; 
vitamin B-12 1 mannitol, 3.33; choline chloride, (70% solution), 71.50; cerelose, 887.8.  
Mineral mix contained the following (g/kg mix): CaCO3, 139.7; CaHPO4, 166.6; K2HPO4, 
133.6; NaCl, 21.2, MgSO4, 49.5; ZnCO3, 0.8; MnSO4.H2O, 0.61; CuSO4.5H2O, 0.66; KI, 
0.0033; CrK(SO4).12H2O, 0.048; Na2SeO3, 0.015; Na2MoO4.2H2O, 0.0063, cerelose,481.1 
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Blood analysis 
Hematocrit was measured by centrifugation of blood and expressed as the volume 
percentage of red blood cells. Hemoglobin concentration was measured using a Hemoglobin 
determination kit (Biodiagnostic Inc., Egypt). Serum iron concentration and total iron 
binding capacity (TIBC) using iron and (TIBC) kit (Biodiagnostic Inc., Egypt).Transferrin 
saturation (TS) was calculated from the ratio of serum iron/TIBC. 
Catalase assay 
Catalase activity was determined in plasma and kidney tissue after homogenate preparation by 
tissue perfusion with a PBS (phosphate buffered saline) solution, pH 7.4 containing 0.16 mg / 
ml heparin to remove any red blood cells and clots prior to dissection. Tissue was homogenized 
in 5-10 ml cold buffer (50 mM potassium phosphate, pH 7.5. 1 mM EDTA) per gram of tissue; 
the homogenate was then centrifuged at 10,000 rpm for 15 minutes at 4 °C. The supernatant 
was removed and stored on ice. If the assay was not conducted on the same day, the sample was 
frozen at -80°C. Catalase activity was estimated using a catalase assay kit (Biodiagnostic Inc., 
Egypt). 
Calculation of iron bioavailability and feed efficiency 
The iron (Fe) bioavailability from test meals was calculated for each animal based on initial 
and final body weights, the initial and the final hemoglobin concentrations, and the amount 
of Fe consumed during the repletion period. The initial and final concentration of 
hemoglobin-Fe was computed according to equations 1, 2 respectively, assuming that 7.5% 
of the body weight is blood and that hemoglobin contains 3.35mg Fe per gram as defined 
previously [12]. 
The relative Fe bioavailability (equation 3) was calculated by dividing the % Fe 
bioavailability from the test meals by the % Fe bioavailability for ferrous sulfate [RBV = (Fe 
bioavailability from diets/Fe bioavailability from FeSO4) × 100]. The relative liver weight 
was calculated by dividing the liver weight by the total body weight. The Fe status was 
evaluated by determining the Fe stored in the liver for each rat. Feed efficiency was also 
calculated according to equation 4. 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Equation (1) 
Initial Hb Fe [mg] = initial BW × (7.5 ml blood/100 g BW) × (initial Hb g/ 100ml) × (3.35mg 
Fe/1g Hb) 
Equation (2) 
Final Hb Fe [mg] = final BW × (7.5ml blood/100g BW) × (final Hb g/100ml) × (3.35mg 
Fe/1g Hb) 
Where: BW = body weight, and Hb = hemoglobin. 
Equation (3) 
Fe bioavailability [%] = (final Hb Fe [mg] - initial Hb Fe [mg])/Fe consumed [mg] 
Equation (4) 
Feed efficiency % = BW gained/ total food intake  
Where: BW gained = final BW – initial BW BW: body weight. 
Tissue preparation for iron determination 
After 56 days, animals were euthanized and their livers, hearts, kidneys, and spleens were 
removed. 1-2 g of tissue was transferred into borosilicate test tubes and concentrated nitric 
acid and perchloric acid were added to the contents. The contents were heated to 85°C for 24 
h followed by 110°C for 5h. Digestion was determine to be complete by the appearance of a 
colorless solution [13]. The iron concentration of samples was measured by inductively 
coupled plasma emission spectrometry (ICPS-1000 II, Shimadzu, Faculty of Agriculture, 
Cairo University). 
Histological examination of tissues 
Tissues derived from liver, kidney, and heart were stained with Hematoxylin-Eosin (H&E) 
for histological examination, while the spleen was stained with Perls’ Prussian blue to 
evaluate iron accumulated in different groups. Histological examinations of rat tissues were 
performed in Cairo University, Faculty of Veterinary medicine as follows: Tissue samples 
were fixed for 48 hours in neutral buffered formalin (NBF). Following the fixation 
procedure, tissues were dehydrated through increasing concentrations of ethanol and 
embedded in paraffin.  Sections approximately 5-7 µm thick were cut from the paraffin 
blocks and stained with H&E for routine histological examination, and with Perls’ Prussian 
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blue for iron pigment analysis. 
Statistical analysis 
All data obtained for yeast experiments reflects the mean of identical triplicate samples ± the 
standard error. Where appropriate, statistical variation was determined using a two tailed 
Student T-Test. A significant difference was identified at the 5% confidence level (P< 0.05). 
For rat analysis, in each instance sample groups were comprised of 8 newly weaned 
‘young’ individuals, with males and females considered to be identical as described 
previously. Data was analyzed using a two tailed Student t-test to determine significant 
differences between trial and control samples. A significant difference was identified at the 
5% confidence level (P< 0.05).  
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Results 
 
Yeast growth and iron accumulation- Yeast cells were grown at different concentrations of 
iron in growth media in order to study the effect of iron concentration in growth medium on 
the yield of cells, iron accumulation in cells and one of mail baking properties of the produced 
cells (leavening ability). Results clearly showed that the yield of S.cerevisiae cells increased 
as the concentration of iron increased  until  the  iron  concentration  reached  32  mM  Fe  in  
medium  (1%  iron  salt)  but  at  higher concentrations of iron the yield of cells decreased as 
the iron concentration increased (Fig.2A ). The amount of iron accumulated in yeast cells also 
increased and reached up to 15 mg/g at 32 mM Fe in medium (1% iron salt), while above that 
concentration (64 and 128 mM) it dropped again. Yeast cells accumulated about 11 mg Fe/g 
dry weight at 64 mM iron concentration, while the addition of 128 mM Fe inhibited iron 
uptake by yeast cells, which was only 7 mg Fe/g (Fig.2B). 
Effect of iron concentration on leavening ability- Leavening ability was studied for 
yeast cells produced at different concentrations of iron. Data in Fig.2C revealed that all 
yeast cells grown on different iron concentrations gave leavening ability higher than the 
control (grown on basal medium).  The  leavening  ability  of  yeast  cells  increased  up  to  32  
mM  Fe  in medium,  while  above  this  concentration  it  dropped  again  but  still  higher  
than  control  and  the concentration of 1 % (32 mM Fe) improved the leavening ability by 
50 % than control. 
Statistical  evaluation  of  different feeding  treatments-  Results  in  Table 1  indicate  that  
the differences in final body weights of rats from different groups were non-significant at 
both 5 % and1 %, so this suggests that there is no significant difference between all 
treatments. On the other hand,  significant  increases  in  body  weights  of  rats  were  
observed  in  all  groups,  although  the increase in group 1 (fed on iron deficient diet) was 
the least significant increase. Moreover, Table 2  shows  that  the  increase  of  hemoglobin  
levels  in  all  groups  were  significant  except  in group 3 (fed on diet containing iron salt 
plus yeast) which was non-significant at the level of 1 % and significant at 5 %. On the 
other hand, there was a significant increase in hemoglobin levels of rats from groups 4 and 
5 when compared with other treatments groups 2 and 3; these results prove clearly  that  
both  groups  4  and  5  achieved  better  results  than  other  treatments.  Also  when 
comparing hemoglobin results from  groups 4 and 5 with those from control group, it was 
noticed that differences between hemoglobin levels of these groups and control group are 
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not significant but  the  result  of  group  4  was  less  significant  (closer)  to  control  group  
which  give  this  group (treatment) the advantage on the other group (group 5). 
Iron bioavailability and feed efficiency- Feed efficiency and iron bioavailability were 
studied and calculated during treatment period (4 weeks). Results indicate that animal 
groups fed on iron enriched yeast (4 and 5) gave the highest feed efficiency (10.9 %) when 
compared with other anemic groups (1, 2 and 3). These groups (4 and 5) gave 90.83 % of 
feed efficiency of control group (which was fed normally), also the feeding efficiency of 
groups fed on iron enriched yeast was increased 1.16 fold when compared with group 2 
which was fed on basal medium plus inorganic iron salt(Fig.3A and Table 3). 
Regarding iron bioavailability, results obtained from Table 4 and Fig.3B show that the Fe in 
group 4  (fed  on  iron  yeast  15  mg/g)  was  significantly  more  bioavailable  compared  to  
other  groups (p<0.01), also the iron bioavailability in group 5 was more than other treatments 
in groups 2 and 3. Results showed that Fe bioavailability increased to 22.46 % in group 5 
when compared to that of control group where it was about 19.44 %, while Fe in groups 2 
and 3 was less bioavailable than control group (16.11 % and 12.93 % respectively). The 
highest Fe bioavailability was obtained in group 4 reached to about 36.35 %. Relative iron 
bioavailability (RBV) gave the same trend of iron bioavailability  and  increased  in  groups  4  
and  5  to  give  186.98  and  115.53  %  of  control  group, while (RBV) remained less than 
control in the other groups. 
Blood parameters- Based  on  hemoglobin  concentration  and  hematocrit  value,  iron  in  
groups  4  and  5  (fed  on  iron enriched yeast) was more bioavailable in rats and cured iron 
deficiency when compared with other groups (1, 2 and 3), as shown in Table 5. In groups 
2 and 3, hemoglobin concentration was less than  that  in  the  control  group,  whereas  the  
hematocrit  value  was  also  slightly  less  than  that  in control  group  at  the  end  of  
treatment  period,  indicating  that  the  Fe  bioavailability  of  the  iron enriched yeast is 
better than other treatments for recovery from iron deficiency. The recovery of iron 
deficiency in groups 2 and 3 was poor when compared to that in groups 4 and 5, assuming 
that the iron sources of iron enriched yeast are more effective than iron salt such as ferric 
sulfate (group2). In the group supplemented with dry yeast besides iron salt (group 3) 
yeast cells might have functioned  as  absorption  inhibitor  decreasing  the  bioavailability  of  
iron  in  rats When iron concentration in serum compared between different treatments 
(groups 2, 3, 4, and 5) results showed that group 4 was subjected to the best treatment 
(iron enriched yeast 15mg Fe/g dry weight) and the iron concentration in serum was similar 
to that of control group, whereas iron concentrations in serum of groups 2 and 5 were 
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nearly equal but less than control group. Treatment of group 3 was the poorest one among 
other treatments and only a slight increase of serum iron was observed when compared to 
negative control (group 1) fed on iron deficient diet.  Similar results were obtained when 
comparing total iron binding capacity (TIBC) and transferrin saturation (TS) in different 
groups.  Results obtained from hemoglobin analysis showed that groups 4 and 5 were 
subjected to the best treatments than other treatments, whereas group 4 also gave the best 
results in other blood parameters studied when compared to other groups. 
Enzymatic  activity  of  iron  dependent  enzyme  (catalase  activity)-  Results  shown  in  
Fig.3C indicates that the iron restricted diet didn't affect the catalase activity in plasma 
during moderate iron deficiency anemia development (4 weeks) period in this experiment 
this may be because the period was not enough to affect the catalase activity in plasma. 
Catalase activity in kidney was also studied. Fig.3D shows the catalase activity in kidney 
tissues of rats from different groups. In contrast of plasma, results obtained from figure 3D 
showed that the catalase activity in kidney tissues of anemic rats decreased.  Different 
treatments raised the catalase activity from 70 U/g tissue in anemic rats to 90 U/g tissue in 
group 2 (iron salt added), 110 U/g tissue in group 3 (iron salt and dry yeast added), 145 U/g 
tissue in group 4 (iron enriched yeast 15 mg Fe/g diet added) and 115 U/g tissue in group 
5 (iron enriched yeast 30 mg Fe/g diet added). Although  the  improvement  was  less  than  
aimed,  the  previous  results  suggest  that  the  treatment applied in group 4 (iron enriched 
yeast 15 mg Fe/g diet) is the best treatment that can be used in the treatment of iron 
deficiency, but it may need more time than used in this experiment (4weeks) to achieve 
complete recovery of catalase activity in kidney tissues. 
Iron accumulation in tissues- Data shown in Fig.3E shows that the reduction of iron 
concentration in liver tissues was about 34% (from 0.93 µmol/g in control group to 0.61 
µmol/g in anemic rats group 1) but it was completely recovered in group 2 to reach 1.03 
µmol/g, but the highest concentration of iron was accumulated in liver tissues of rats fed on 
iron enriched yeast in group 4 which was 1.29µmol/g. On the other hand, iron concentration in 
spleen tissues shown in Fig.3Fwas gradually increased in different treatments from 
1.93µmol/g in anemic rats (group 1) to 2.6µmol/g and 4.85µmol/g in groups 2 and 3 
respectively, and reached its maximum of 5.9 and 6.1µmol/g in groups 4 and 5, respectively. 
Histological examination of tissues- Analysis of rat liver sections (Figure 4A) indicated that 
livers from the control group showed no histological changes apart from hydropic degeneration 
of hepatocytes (Ctrl).  However, liver of rat from group 1 (G1) revealed vacuolar degeneration of 
hepatocytes. Examined liver of rat from group 2 (G2) showed marked dilatation and 
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congestion of central vein as well as hydropic degeneration of hepatocytes. Meanwhile, liver 
of rat from group3 (G3) revealed no histopathological changes.  Liver  of  rat  from group  4  
(G4) showed  vacuolar  degeneration  of  some  hepatocytes.  Moreover,  liver  of  rat  from  
group  5  (G5) showed  vacuolar  degeneration  of  hepatocytes.  Histological study of liver 
showed that a clear damage was observed in the livers of anemic rats (G2), but the damage 
was decreased by different treatments, and the best results were obtained in groups 4 and 5. 
Kidneys of rats from control group (Ctrl) revealed the normal histological structure of renal 
parenchyma. Meanwhile,  kidneys  of  rats  from  group  1  showed  peritubuler  leucocytic  
cells  infiltration  and perivasculitis (G1). However, kidneys from rats of group 2 revealed 
no histological changes (G2). Examined kidneys of rats from group 3 showed vacuolation 
of epithelial lining renal tubules and focal interstitial nephritis (G3).  No histological 
changes were noticed in kidneys of rats from groups 4 and 5 (G4) and (G5). The previous 
results show that the kidneys of rats from groups 2, 4, and 5 were recovered from damage 
occurred due to anemia in group 2 (Fig.4B). 
Examination of heart of rat from control group revealed no histopathological changes (Ctrl). 
On the other hand, heart of rat from group 1 showed myocarditis with mononuclear 
leucocytic cells infiltration (G1).  However,  heart  of  rat from group  2  showed  no  changes  
except  slight  intermuscular  edema  (G2).  Vaculations of some cardiac myocytes was 
noticed in heart of rats from group 3 (G3). Meanwhile, hearts of rats from groups 4 and 5 
showed no histopathological changes (G4) and (G5). The results of microscopically studied 
heart sections showed that the severe damage occurred in hearts of anemic rats in group 1 
(G1), was completely recovered in rats of groups 4 and 5(Fig.4C). 
Sections of spleens were stained with Perls’ Prussian blue to evaluate iron accumulated in 
different groups. Fig.4D shows iron accumulated in spleens of rats from different groups. 
Examination of spleens  of  rats  from  control  group  showed  marked  deposition  of  
greenish  blue  hemosiderin pigment,  indicating  iron  accumulated  in  tissues  (Ctrl).  Examined 
spleens of rats from group 2 showed a very few deposits in spleen tissues (G1). Moreover, the iron 
deposition in groups 2 and 3 was  increased  but  still  less  than  control  group,  (G2)  and  (G3).  
However  the  iron  deposition  in spleen  tissues  from rats  in  groups  4  and  5  was  clearly  
increased  and  recurred  as  control  group, (G4) and (G5). These results support the results of 
iron accumulated in tissues of spleen of rats of different groups. 
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Discussion 
Possible explanations for lower iron accumulation in yeast cells at higher concentrations in the 
medium could be found in some previous investigations. Lesuisse et al. [14] found out that 
higher concentration of  Fe(III)  in  the  medium  caused  decrease  of  negative  potential  at  
yeast  cell  surface  due  to saturation  of  negative  groups  near  iron  transporters,  which  
otherwise  participate  in  iron  uptake. Consequently,  the  accumulation  of  iron  would  be  
inhibited,  what  is  consistent  with  previous results, too. On the other hand, Tuttle et al. 
[15]discussed the possibility of iron efflux out of yeast cells at higher concentrations of iron in 
the cell interior. This could also be a reason for lower amounts of accumulated iron in 
S.cerevisiae at concentrations of ammonium Fe (III) citrate higher than 32 mM. 
. In humans, the capacity of iron absorption from the diet depends on various factors including 
the amount of iron in the body, the rate of erythrocyte production, the amount and kind of 
iron in the diet, and the presence of absorption enhancers and inhibitors in the diet [16], [17].  
The  histological  study  of  tissues  from  liver,  kidney,  heart,  and  spleen  of  rats  from  
different groups showed that the severe damage occurred in tissues of anemic rats group 1, 
was completely recovered after treatment by iron enriched yeast in groups 4 and 5. 
However other treatments in groups 2 and 3 may require more time to achieve the same 
results obtained in treatment by iron enriched yeast, also only slight histological 
differences can be observed when comparing group 4 and  group  5,  leading  that  both  
treatments,  15  mg  Fe/Kg  diet  (group  4)  and  30  mg  Fe/Kg  diet (group  5),  of  iron  
enriched  yeast  have  the  same  efficiency  when  used  to  cure  moderate  iron deficiency 
anemia. 
In conclusion, this study demonstrates that the iron enriched baker’s yeast prepared in 
presence of 32 mM Fe in growth medium has the best baking properties (leavening ability) 
of both parent and other Fe concentrations grown cells, with improvement of biomass 
produced. The used strain was also  proved  to  accumulate  the  highest  content  of  Fe  (15  
mg/g)  at  this  concentration  (32  mM) among other concentrations tested, and achieved the 
most bioavailability of iron when used in the diet of anemic rats ahead of other treatments 
by inorganic iron salts. Also the severe damage occurred in tissues of anemic rats was 
completely recovered after treatment by iron enriched yeast, However  salt-based   
treatments  may require  more  time  to  achieve  the  same results. It is suggested that the use of 
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iron-enriched yeast products may lead to the prevention of anemia in compromised 
individuals, or the ability to recover from moderate iron deficiency. 
  More advanced studies about the effects of iron enriched baker’s yeast on the quality of 
bread loaf are undergoing for pave the way for the use of iron enriched yeast industrially for 
the production of bread. 
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Highlights 
 
• Iron enriched yeast was prepared by cultivation of yeast cells at different iron 
concentrations and best concentration was determined with no effect of yeast growth 
or baking properties. 
• Anemic rats were fed on different diets containing either inorganic iron salt or iron 
enriched yeast as iron source.   
• Feeding efficiency and different haematological incidences were followed up for all 
groups. 
• Histological study was performed for liver, heart, kidney and spleen tissues in all 
groups.   
• Feeding anemic rats with supplemented yeast leads to better results in recovery from 
iron deficiency when compared to other diets containing inorganic iron salt as iron 
source.   
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Figure legends 
 
Fig.1: Design of rat feeding experiments  
Fig.2: Effect of growth media iron concentration on yield of yeast cells (A), iron 
accumulation in cells (B) and leavening ability (C). Data represents the average of triplicate 
samples and the standard error is indicated by the error bars.   
Fig.3:  Feed efficiency (A) , iron bioavailability (B), catalase activity in plasma (C) and 
kidney tissue (D), and iron concentrations in liver (E) and spleen (F) of each group of rats. 
Data represents the mean of 8 rats and the standard error is indicated by the error bars .   
Fig.4  
(A) Liver sections stained with H&E from each sample group. Red arrows indicate 
abnormalities in the tissue.  
(B) Heart sections stained with H&E from each sample groups. Red arrows indicate 
abnormalities in the tissue.  
(C) Kidney sections stained with H&E from each sample group.  In each instance no major 
differences were observed. 
(D) Spleen sections stained with Prussian blue from each sample group. Red arrows indicate 
abnormalities in the tissue.  
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 Tables 
 
 
Table.1: Initial and final mean values of rats' body weights (with *LSD values) from different groups during 
treatment period 
 
Treatments Time in days 
21 (0 time) 56 (35) 
Control 114.33±3.5 164.83±10.1 
Group 1 97.80±8.1 126.80±11.1 
Group 2 130.67±8.5 170.33±6.2 
Group 3 120.33±8.2 161.50±10.8 
Group 4 115.67±8.7 161.50±10.6 
Group 5 115.50±7.8 161.40±11.2 
Values are mean ± SE, n=8 all differences in body weights were significant at p<0.05 for each group. 
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Table.2: Initial and final mean values of rats' hemoglobin (with LSD values) from different groups during 
treatment period 
 
Treatments Time in days 
21(0 time) 56(35) 
Control 143.50±6.4 162.00±8.2 
Group 1 126.00±7.7 90.20±10.2 
Group 2 109.60±10.6 130.30±12.5 
Group 3 109.10±4.3 119.20±11.5 
Group 4 112.60±10.5 160.00±9.8 
Group 5 112.00±10.6 158.16±4.2 
Values are mean ± SE, n=8 all differences in hemoglobin values were significant at p<0.05 for each group. 
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Table.3: Body weight, total food intake, and feed efficiency of rats. Rats were under-fed to make sure that all 
groups will consume the assigned amount of food. The food consumption of wistar rats investigated was 18g/day 
and 630 g over 35 days 
Group *Final B.W (g) 
*Gained weight 
(g) 
 
*Consumed food 
(g) 
Feed efficiency 
% 
Ctrl 164.8±13.2 50.5±9.8 
420.00 12.0 
Fe (-) 
Group (1) 126.8±14.3 29.0±8.6 
420.00 6.9 
Fe – S 
Group (2) 170.3±13.6 39.7±7.9 
420.00 9.4 
Fe – S Yeast 
Group (3) 
161.5±28.3 
 
41.1±9.1 420.00 9.7 
Fe – Yeast 15 
Group (4) 161.5±26.8 46.0±10.1 
420.00 10.9 
Fe – Yeast 30 
Group (5) 161.4±15.7 45.8±9.7 
420.00 10.9 
*Values ± SE, p<0.05 
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Table.4: Indices of Fe bioavailability in different groups during treatment period 
Group 
Initial Hb Fe* 
mg 
Final Hb Fe* 
mg 
Fe Intake* 
mg 
Fe 
bioavailabilit
y* 
% 
Relative Fe 
bioavailabilit
y* 
(RBV) % 
Ctrl 4.15± 0.3 6.60±0.4 12.60±0.5 19.44±3.1 100 
Fe (-) 3.09±0.2 3.01±0.2 3.00±0.1 -2.60±1.1 -13.37 
Fe – S 3.45±0.2 5.48±0.3 12.60±0.2 16.11±2.2 82.87 
Fe – S Yeast 3.32±0.1 4.85±0.3 12.60±0.3 12.93±2.1 66.51 
Fe – Yeast 15 3.28±0.3 5.57±0.2 6.30±0.4 36.35±4.2 186.98 
Fe – Yeast 30 3.11±0.2 5.94±0.3 12.60±0.4 22.46±3.4 115.53 
*Values ± SE, n=8, p<0.05
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Table.5: Hemoglobin, iron concentration, TIBC, and TS in the serum of rats 
 
Group 
 
*Final 
Hemoglobin 
(g/l) 
 
*Hematocrit 
(Volume fraction) 
 
*Serum iron 
(µmol/l) 
*Total iron 
binding 
capacity 
(TIBC) 
(µmol/l)  
 
*Transferrin 
saturation 
TS 
(%) 
Ctrl 162.0±13.5  
 
0.44±0.06 
 
26.7±2.8 60.5±3.5  
 
44.1±2.1  
 
Fe (-) Group (1) 90.2±10.3  
 
0.35±0.02 
 
11.6±2.3 30.7±2.1  
 
37.7±1.8  
 
Fe – S Group (2) 130.3±12.6  
 
0.39±0.07 
 
22.9±1.5 43.5±3.8  
 
52.5±3.1  
 
Fe – S Yeast 
Group (3) 
119.2±11.5  
 
0.33±0.09 
 
14.5±2.1 35.3±2.4  
 
41.5±2.9  
 
Fe – Yeast15 
Group (4) 
 
158.2±15.4  
 
0.42±0.06 
 
26.2±3.8 48.9±3.6  
 
53.0±3.6  
 
Fe – Yeast30 
Group (5) 
 
160.0±10.3  
 
0.46±0.08 
 
21.9±3.6 40.9±3.3  
 
56.5±3.4  
 
*Values ± SE, n=8, p<0.05 
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